Literature DB >> 8457383

Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage.

T F Schulz1, J D Reeves, J G Hoad, C Tailor, P Stephens, G Clements, S Ortlepp, K A Page, J P Moore, R A Weiss.   

Abstract

It has been suggested that the V3 domain of human immunodeficiency virus type 1 (HIV-1) isolates has to interact with a cell-surface-associated or endosomal proteinase during virus entry into susceptible cells. To investigate this hypothesis, we examined the effect of several mutations in the V3 loop on its susceptibility to proteolytic cleavage by thrombin and cathepsin E and compared it with the effect of these mutations on viral infectivity. The data obtained indicate that, if an interaction between the V3 loop and a proteinase is indeed crucial for viral entry, the substrate requirements for such a proteinase(s) would have to be very complex. In particular, it seems unlikely that a single enzyme with a unique specificity would be able to interact with all of the different HIV-1 and HIV-2/SIV strains isolated so far. Therefore, one would have to postulate the involvement of several cellular proteinases, or proteases with multiple specificities, in V3-based viral tropism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8457383     DOI: 10.1089/aid.1993.9.159

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

2.  Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.

Authors:  L Stamatatos; A Werner; C Cheng-Mayer
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

3.  Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.

Authors:  Hsu-Tso Ho; Li Fan; Beata Nowicka-Sans; Brian McAuliffe; Chang-Ben Li; Gregory Yamanaka; Nannan Zhou; Hua Fang; Ira Dicker; Richard Dalterio; Yi-Fei Gong; Tao Wang; Zhiwei Yin; Yasutsugu Ueda; John Matiskella; John Kadow; Paul Clapham; James Robinson; Richard Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.

Authors:  M A Handley; R T Steigbigel; S A Morrison
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.

Authors:  Sophia W Li; Bin Yu; Gabriel Byrne; Meredith Wright; Sara O'Rourke; Kathryn Mesa; Phillip W Berman
Journal:  Biotechnol Bioeng       Date:  2019-06-10       Impact factor: 4.530

6.  Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  James M Binley; Rogier W Sanders; Aditi Master; Charmagne S Cayanan; Cheryl L Wiley; Linnea Schiffner; Bruce Travis; Shawn Kuhmann; Dennis R Burton; Shiu-Lok Hu; William C Olson; John P Moore
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells.

Authors:  S Hallenberger; M Moulard; M Sordel; H D Klenk; W Garten
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.

Authors:  N Sullivan; Y Sun; J Binley; J Lee; C F Barbas; P W Parren; D R Burton; J Sodroski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Authors:  Nancy P Y Chung; Katie Matthews; Helen J Kim; Thomas J Ketas; Michael Golabek; Kevin de Los Reyes; Jacob Korzun; Anila Yasmeen; Rogier W Sanders; Per Johan Klasse; Ian A Wilson; Andrew B Ward; Andre J Marozsan; John P Moore; Albert Cupo
Journal:  Retrovirology       Date:  2014-04-25       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.